JPJin-Lin Peng

Jin-Lin Peng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jin-Lin Peng has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Lei Wang

    Department of Rehabilitation Medicine, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China

    2 shared publications
  • Ai-Lian Chen

    Department of Rehabilitation Medicine, Hunan Provincial People's Hospital & The First Affiliated Hospital of Hunan Normal University, Changsha, 410005, Hunan, PR China

    1 shared publication
  • Ji-Zhou Wu

    The First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China

    1 shared publication
  • Lei Mm Wang

    Department of Rehabilitation Medicine, Hunan Provincial People’s Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, People’s Republic of China

    1 shared publication
  • Lei Wang

    Hunan Provincial People’s Hospital and The First-Affiliated Hospital of Hunan Normal University, China

    1 shared publication
  • Ping-Ping Yin

    Department of Rehabilitation Medicine, Hunan Provincial People's Hospital & The First Affiliated Hospital of Hunan Normal University, Changsha, 410005, Hunan, PR China

    1 shared publication

Latest Publications

  • Genetically mediated causal relationship between gut microbiota composition and childhood obesity

    by Lei Wang, Ya-Hui Xiao, Zhen-Jiang Hu, Ping-Ping Yin, Ai-Lian Chen, Jin-Lin Peng

    Gut microbiota (GM) plays a critical role in maintaining human health and modulating the pathogenesis of various diseases. This study aimed to investigate the causal relationship between gut microbiota and childhood obesity using Mendelian randomization. In accordance with preset thresholds, independent genetic loci significantly related to the relative abundance of GM were extracted as instrumental variables using GM genome-wide association study (GWAS) data from the MiBioGen database and childhood obesity GWAS data from the IEU Open GWAS database. Inverse variance weighting was used to examine the causal relationship between GM and childhood obesity. An increase in Akkermansia and Butyricimonas abundance can reduce the risk of obesity in children (OR = 0.476, 95% CI: 0.311-0.726, P = 0.001; OR = 0.682, 95% CI: 0.471-0.990, P = 0.044). Ruminiclostridium9 abundance increased the risk of childhood obesity (OR = 2.051, 95% CI: 1.069-3.932, P = 0.031). Beneficial GM members Akkermansia and Butyricimonas were positively associated with reduced obesity risk in children. Ruminiclostridium 9 was identified as a potential risk factor for childhood obesity. This study provides genetic evidence supporting a potential causal relationship between GM composition and childhood obesity, offering valuable insights for future research and preventive intervention strategies. Gut microbiota (GM) plays a critical role in maintaining human health and modulating the pathogenesis of various diseases. GM-based interventions have emerged as promising therapeutic approaches for childhood obesity. This study aimed to investigate the causal relationship between gut microbiota and childhood obesity using Mendelian randomization methods, thereby providing genetic evidence to support the potential of GM-targeted strategies in the prevention and management of this condition. The findings reinforce prior observational evidence by demonstrating a causal association between specific gut microbial taxa and childhood obesity. These results provide valuable insights that may guide future research and the development of novel therapeutic interventions.

  • Open Access

    Association of hypoxia-inducible factor 1α expression with susceptibility to hepatitis B virus-related hepatocellular carcinoma: A meta-analysis

    by Lei Wang, Jin-Lin Peng

    Hypoxia-inducible factor 1α (HIF-1α) triggers tumorigenesis and progression in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Inconsistent findings have been reported on the influence of HIF-1α over-expression on the clinical outcomes of HBV-related HCC. This study aims to clarify the role of HIF-1α overexpression in the tumorigenesis and prognosis of HBV-induced HCC. Systematic and comprehensive search of online papers was carried out to elucidate the contribution of HIF-1α expression to susceptibility of HBV-induced HCC. STATA 12.0 software was utilized to analyze available data extracted from all eligible literature. Publication bias and sensitivity were comprehensively analyzed. A total of 23 published studies involving 2244 subjects were finally screened. The HIF-1α expression was remarkably upregulated in HBV-induced HCC tissues than in normal liver tissues, non-tumorous tissues, paraneoplastic tissues, and non-HBV HCC tissues. The high HIF-1α expression tended to be positively related to capsular infiltration (odds ratio (OR) 1.767; 95% confidence interval (CI) 1.058, 2.950). The HIF-1α expression was relevant to lymph node metastasis (OR 3.778; 95% CI 1.666, 8.568). High levels of HIF-1α expression tended to be closely implicated in portal vein invasion (OR 6.728, 95% CI 2.191, 20.656) but were irrelevant to alpha-fetoprotein, cirrhosis, Edmondson grading, tumor size, age, gender, and histological grade. Analysis of pooled data showed that HIF-1α was not statistically relevant to poor overall survival in HBV-related HCC. Our data provides compelling evidence that HIF-1α overexpression may imply a greater probability of invasion and metastasis in patients with HBV-induced HCC.

  • Open Access

    METTL5 serves as a diagnostic and prognostic biomarker in hepatocellular carcinoma by influencing the immune microenvironment

    by Lei Wang, Jin-Lin Peng

    Despite the abnormal expression of 18S rRNA m6A methyltransferase METTL5 being reported in some types of human malignancies, but its effect on hepatocellular carcinoma (HCC) remains to be unclear. This study aims to elucidate the influences of METTL5 on the carcinogenesis and progression of HCC. Expressions of METTL5 gene, transcript, protein, and promoter methylation in HCC were examined through multiple databases, c-BioPortal was used to confirm the genomic alterations of METTL5, the biological functions, target networks of kinases and microRNAs of METTL5, and its interactive differential genes were investigated through LinkedOmics. The possible correlation of METTL5 with the tumor-related infiltration of immune cells for HCC were explored comprehensively by using the online tools of TIMER and TISIDB. Expressions of METTL5 gene, mRNA, and protein were considerably overexpressed in HCC samples in comparison with healthy samples. The high methylation of the METTL5 promoter was observed in HCC tissues. Elevated METTL5 expression exhibited unfavorable survival outcomes in HCC patients. METTL5 expression were enriched in the signaling pathways of ribosome and oxidative phosphorylation, mismatch repair, and spliceosome through the involvement of several cancer-related kinases and miRNAs. The METTL5 expression has a positive correlation with the infiltration degree of B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells in HCC. Marker genes of tumor immune-infiltrated cells have strong connection with METTL5. Furthermore, the upregulation of METTL5 was strongly correlated with the immune regulation of immunomodulators, chemokines, and chemokine receptors in the immune microenvironment. The oncogenesis and development of HCC are closely related to METTL5 expression, and the overexpression of METTL5 resulted in the poor survival outcome of HCC patients by regulating tumor immune microenvironment.


  • Open Access

    Nomogram to predict the prognosis of patients with AFP-negative hepatocellular carcinoma undergoing chemotherapy: A SEER based study

    by Lei Mm Wang, Jin-Lin Mm Peng, Ji-Zhou Wu

    This study aimed to formulate reliable nomograms for predicting the outcomes of α-fetoprotein (AFP)-negative hepatocellular carcinoma (HCC) patients after chemotherapy. HCC patients with normal AFP expression who received chemotherapy were screened and evaluated from the surveillance, epidemiology, and end results database. The prognostic factors for predicting outcomes of HCC patients undergoing chemotherapy were chosen by analyzing the results of Cox analyses. Then, a nomogram integrating the prognostic factors was established. The discrimination ability of the nomogram was evaluated with computation of area under the curve (AUC) and calibration curve. A total of 2424 patients with AFP-negative HCC undergoing chemotherapy were identified. The median overall survival (OS) for HCC patients undergoing chemotherapy was 33 months. Age, race, pathologic grade, N stage, M stage, surgery, and lung metastases were significantly linked to OS. These relevant factors were incorporated into the nomogram. AUC values of the prognostic nomogram for 3- and 5-year OS were 0.696 and 0.706 in the training groups, which were superior to those of the tumor node metastasis (TNM) stage (0.641 and 0.671) in training groups. The calibration curves indicated a high consistency between the predicted probability of nomograms and the actual observation. The validation groups produced AUC values of 0.674 and 0.736 for 3- and 5-year OS, which were superior to those of the TNM stage (0.601 and 0.637) in validation groups. The results revealed significantly unfavorable OS in the high-risk group (P < .001). Nomograms to accurately predict the OS for AFP-negative HCC patients after chemotherapy were established and exhibited a more accurate predication than the conventional TNM staging system.